Latest Inostics GmbH Stories

BALTIMORE and HAMBURG, Germany, April 9, 2013 /PRNewswire/ -- A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics' BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST patients than testing conventional biopsies. Therapies targeted to specific cancer-causing mutations may be the most promising strategy in cancer treatment. However, inter- and intra-tumor heterogeneity pose a...

BALTIMORE, Maryland and HAMBURG, Germany, June 18, 2012 /PRNewswire/ -- Two studies published back-to-back in last week's Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure was observed. The group led by Alberto Bardelli, PhD of the University of Torino, Italy describes the development of secondary resistance mutations to the anti-EGFR monoclonal...

HAMBURG, Germany, May 11, 2011 /PRNewswire/ -- In response to the growing interest in the sensitive blood-test for the detection of tumor-specific DNA-molecules, Inostics GmbH (Hamburg, Germany) has founded a US subsidiary. Inostics' non-invasive test based on the BEAMing-Technology is one of the most sensitive methods available today for the detection of tumor specific mutations and is already used in studies by pharmaceutical and biotechnology companies. The founding of Inostics Inc....